Published in Blood Weekly, April 12th, 2001
The report, published in Haemophilia, indicates Monoclate-P can be safely tolerated in pediatric patients with few adverse effects.
Results of the study were based on an open-label clinical trial of 30 patients. Eighteen (severe) and 12 (moderate) hemophiliacs were given Monoclate-P for up to 34 months, during which time they were monitored for hepatitis viruses and human immunodeficiency virus (HIV).
None of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.